Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04756401 · OUTCOME

Number of Patients With a Grade 3 or Greater Adverse Event

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · Source last updated 2026-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number of patients with at least one grade 3 or greater AE, regardless of attribution, will be reported.

Groups in this outcome

Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)

Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)8

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number of patients with at least one grade 3 or greater AE, regardless of attribution, will be reported.
groups
  1. description
    Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\> \> Carfilzomib: Given IV\> \> Daratumumab: Given IV\> \> Dexamethasone: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> Selinexor: Given PO
    id
    OG000
    title
    Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
2 years
title
Number of Patients With a Grade 3 or Greater Adverse Event
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice